Use of Mendelian randomization to better understand and treat sepsis

James A. Russell1,2*, Nuala J. Meyer3 and Keith R. Walley1,2

© 2022 The Author(s)

Discovering novel therapies and defining the causal contribution of genes, proteins and lipids is challenging in sepsis, because sepsis is so heterogeneous; effective therapies in one patient may not be effective in another, explaining in part why sepsis trials have not been very successful.

We highlight Mendelian randomization (MR), a statistical methods that first helps establish causal relationships between intermediate phenotypes such as plasma proteins and clinical phenotypes using genetics. In sepsis, there are innumerable studies showing significant associations between proteins, metabolites, other biomarkers and outcomes, yet the causal contribution of biomarkers is highly uncertain, potentially due to confounding, reverse causation, or because, for example, inflammatory markers are non-specific epiphenomena. Genetics are a powerful tool to interrogate which intermediate traits, including plasma proteins, metabolites, or even radiographic features, contribute to a disease. MR also enhances prognostic and predictive enrichment of sepsis trials by better defining biologically relevant clinical subgroups. The technique has been successfully used to define several traits with causal contributions to risk for acute respiratory distress syndrome (ARDS) [1–3] and to sepsis mortality [4, 5], highlighting pathways which warrant targeting and identifying specific at-risk populations. Thus, MR holds promise to advance successful precision sepsis trials.

MR uses observational data and genotype as a statistical instrument to estimate an intermediate variable (e.g., protein, metabolite), because humans are randomly “assigned” their genotypes at conception [6, 7]. Underlying MR is the assumption that the portion of the trait that is genetically determined is less vulnerable to measurement error or confounding, and not at risk for reverse causality, since genotype always precedes outcome. MR aids predictive enrichment by separating biologically causal pathways from the numerous non-causal biomarker and outcome associations.

Although MR lacks utility for individual subject classifications, we argue that it has value in preparing for precision medicine trials by highlighting the key variables that classify individuals and that influence disease risk or outcome. Exciting biomarker-enriched sepsis trials [8] and retrospective evaluations suggest that heterogeneity of treatment effect can be predicted by biologically defined subtypes [9, 10] suggesting that precision sepsis treatment might soon be reality.

Mendelian randomization relevance in sepsis

MR is an adaptation of instrumental variable analysis, a tool for causal inference from observational data, wherein the instrument is genotype. In other complex traits, MR very effectively identifies which intermediate variables (e.g., plasma proteins, imaging markers or physiologic measurements) contribute causally to disease, as opposed to being merely correlated [11]. In sepsis, few causal intermediates have been identified, and better elucidation of these traits might focus attention on the most promising targets.

In sepsis, MR links three types of evidence to infer causality, (1) genotype versus intermediate phenotype, (2) intermediate phenotype versus clinical phenotype, and (3) genotype versus clinical phenotype.
Figure 1A illustrates how a statistical instrument (tobacco tax) can infer causality (smoking causes cancer) from observational data. Figure 1B extends these concepts to illustrate how MR rules out alternative explanations for changes in the protein and changes in the phenotype in the absence of a causal relationship between the protein and clinical phenotype (e.g., severity of sepsis could independently cause both). In this case the genotype of the protein, which is randomized at conception according to the independent assortment of alleles, can be used as the instrument. If (1) the genotype of the protein is related to the activity of the protein (e.g., by protein abundance, isoform, or function) and (2) genotype of the protein is also related to the clinical phenotype (e.g., sepsis survival) then alternate explanations are avoided. Thus, the protein likely causally contributes to the clinical phenotype. Note that both cis regulation (genotype of the protein) and trans regulation are relevant, since multi-locus MR uses all variants with strong effect and tests for consistency.

We used Mendelian randomization to answer the following question: do low low-density lipoprotein (LDL) levels increase sepsis mortality? We used Proprotein Convertase Subtilisin/Kexin type 9 PCSK9 genotype and 3-Hydroxy-3-Methylglutaryl-CoA (HMG-CoA) reductase (HMGCR) genotype as instrumental variables with demonstrable influence on LDL concentration [4].

HMG-CoA reductase is the rate-limiting enzyme for cholesterol synthesis; PCSK9 regulates LDL clearance. We reasoned that if both PCSK9 loss-of-function genotype (which increases LDL clearance) and HMGCR loss-of-function genotype (which reduces LDL production) similarly increase mortality, one would conclude that low LDL causes sepsis mortality. However, HMG-CoA reductase genetic score was not associated with increased sepsis mortality, whereas PCSK9 genetic score was associated with decreased mortality. Thus, increased LDL clearance via PCSK9 genotype effects may lower
mortality [4] by increasing LDL-bound pathogen lipid clearance. Furthermore, PCSK9 genotype could be used to enrich trials of PCSK9 inhibitor(s) in sepsis.

MR also shows that body mass index [12] and high-density lipoprotein (HDL) levels causally contribute to sepsis mortality [13, 14] and vitamin D causally contributes to risk of bacterial pneumonia [15].

In another MR example, we evaluated whether native IgG antibody level alters risk of hospitalization due to coronavirus disease 2019 (COVID-19). First, we identified IgG genotypes associated with IgG level (via GWAS catalogue data set from 70 studies), restricting analysis to variants that function as strong statistical instruments (p < 5 x 10^-8). Second, we used the GWAS statistics from the COVID-19 Host Genetics Initiative (freeze 6, B2_(12)ALL_leave_23andme) for COVID-19 hospitalization (n = 24,274) versus non-COVID population (n = 2,061,529) [16]. Genetic variants with a greater effect on IgG levels had a greater effect on decreasing COVID-19 hospitalization (Fig. 1C).

Limitations of MR include the need for large sample sizes and the potential for differential genetic predictors for quiescent versus evoked sepsis traits. Further limitations are inadequate phenotype definition, gene–environment interaction, measurement error, and linkage disequilibrium [17]. There are examples in which the Mendelian randomization assumptions are violated causing biases [17]. Sensitivity analysis can determine the consequences of assumption violations and tries to mitigate such violations [17]. Furthermore, an extension of MR, the MR–Egger method uses tests to determine whether genes have (1) multiple effects—directional pleiotropy—(2) causal effects, and (3) an estimate of the size of the causal effect [18]. However, causal estimates from the MR–Egger method causal estimates can be biased with Type 1 error.

In conclusion, familiarity with Mendelian randomization may help better (1) elucidate causality and (2) enhance selection of patients for trials through enrichment and classify patients likely to benefit, thus catalysing more successful sepsis trials.

Author details
1 Centre for Heart Lung Innovation, St. Paul’s Hospital, University of British Columbia, Vancouver, BC, Canada. 2 Division of Critical Care Medicine, St. Paul’s Hospital, University of British Columbia, Vancouver, BC, Canada. 3 Division of Pulmonary, Allergy, and Critical Care Medicine, University of Pennsylvania Perelman School of Medicine, 3400 Spruce Street, 5038 Gates Building, Philadelphia, PA 19104, USA.

Funding
This study was funded by Canadian Institutes of Health Research (439993) and St. Paul’s Foundation.

Declarations

Conflict of interest
KRW has no disclosures. NJM reports finding to her institution from NIH and Quantum Leap Helathcare Collaborative. She reports consulting for Endpoint Health, Inc.

Open Access
This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 1 April 2022 Accepted: 2 June 2022 Published: 14 September 2022

References
1. Reilly JP, Wang F, Jones TK, Palakkappapa JA, Anderson BJ, Shashaty MGS et al (2018) Plasma angiotensin-2 as a potential causal marker in sepsis-associated ARDS development: evidence from Mendelian randomization and mediation analysis. Intensive Care Med 44(11):1849–1858
2. Du M, Garcia JGN, Christie J, Xin J, Cai G, Meyer NJ et al (2021) Integrative omics provide biological and clinical insights into acute respiratory distress syndrome. Intensive Care Med 47(7):761–771
3. Jones TK, Feng R, Kerchberger VE, Reilly JP, Anderson BJ, Shashaty MGS et al (2020) Plasma sRAGE acts as a genetically regulated causal intermediate in sepsis-associated acute respiratory distress syndrome. Am J Respir Crit Care Med 201(1):47–56
4. Walley KR, Boyd JH, Kong HJ, Russell JA (2019) Low-density lipoprotein levels are associated with, but do not causally contribute to, increased mortality in sepsis. Crit Care Med 47(3):463–466
5. Wang F, Meyer NJ, Walley KR, Russell JA, Feng R (2016) Causal genetic inference using haplotypes as instrumental variables. Genet Epidemiol 40(1):35–44
6. Sheehan NA, Meng S, Didelez V (2011) Mendelian randomisation: a tool for assessing causality in observational epidemiology. Methods Mol Biol 713:153–166
7. He W, Castiblanco J, Walter EA, Okulicz JF, Ahuja SK (2010) Mendelian randomization: potential use of genetics to enable causal inferences regarding HIV-associated biomarkers and outcomes. Curr Opin HIV AIDS 5(6):545–559
8. Kynazopouloou E, Poulakou G, Milonis H, Metallidis S, Adamis G, Tsiakos K et al (2021) Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. Nat Med 27(10):1752–1760
9. Callfee CS, Delucchi K, Parsons PE, Thompson BT, Ware LB, Matthay MA et al (2014) Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials. Lancet Respir Med 2(8):611–620
10. Meyer NJ, Reilly JP, Anderson BJ, Palakkappapa JA, Jones TK, Dunn TG et al (2018) Mortality benefit of recombinant human interleukin-1 receptor antagonist for sepsis varies by initial interleukin-1 receptor antagonist plasma concentration. Crit Care Med 46(1):21–28
11. Zacho J, Tybjaerg-Hansen A, Jensen JS, Grande P, Silleseen H, Nordestgaard BG (2008) Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med 359(18):1897–1908
12. Rogne T, Solligard E, Burgess S, Brumpton BM, Paulsen J, Prescott HC et al (2020) Body mass index and risk of dying from a bloodstream infection: a Mendelian randomization study. PLoS Med 17(11):e1003413

13. Trinder M, Genga KR, Kong HJ, Blauw LL, Lo C, Li X et al (2019) Cholesteryl ester transfer protein influences high-density lipoprotein levels and survival in sepsis. Am J Respir Crit Care Med 199(7):854–862

14. Trinder M, Walley KR, Boyd JH, Brunham LR (2020) Causal inference for genetically determined levels of high-density lipoprotein cholesterol and risk of infectious disease. Arterioscler Thromb Vasc Biol 40(1):267–278

15. Colak Y, Nordestgaard BG, Afzal S (2021) Low vitamin D and risk of bacterial pneumonias: Mendelian randomisation studies in two population-based cohorts. Thorax 76(5):468–478

16. Initiative C-HG (2020) The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic. Eur J Hum Genet 28(6):715–718

17. VanderWeele TJ, Tchetgen EJ, Cornelis M, Kraft P (2014) Methodological challenges in mendelian randomization. Epidemiology 25(3):427–435

18. Burgess S, Thompson SG (2017) Interpreting findings from Mendelian randomization using the MR-Egger method. Eur J Epidemiol 32(5):377–389